Traws Pharma, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$3M
R&D
$12M
D&A
$61K
Operating Income
$-18M
EBITDA
$-18M
Interest Expense
—
Interest Income
$455K
Other Income/Expense
$27M
Pretax Income
$9M
Tax Provision
—
Net Income
$9M
Operating Margin
-640.7%
Net Margin
328.7%
Effective Tax Rate
—
Deferred Tax Assets
$0
Deferred Tax Liabilities
—
DTA Valuation Allowance
$40M
Tax Credit Carryforwards
—
NOL Carryforwards
$30M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.5%
ETR Foreign Differential (pp)
0.1%
Operating Lease Cost
—
Revenue YoY Variation
1134.5%
Income YoY Variation
87.4%